BioSpace News Archive

Eyenuk has been approved to market its EyeArt® AI eye screening system in the European Union for the new uses of detecting age-related macular degeneration (AMD) and glaucomatous optic nerve damage (a sign of glaucoma).

Tonix Pharmaceuticals Holding Corp. today announced that David C. Yeomans, Ph.D., presented data from clinical and nonclinical studies in an oral presentation at the 16th Annual Headache Cooperative of the Pacific (HCOP) Winter Conference on January 27, 2023.

PolyPid Ltd. today announced that it will report its fourth quarter and full year 2022 financial results and operational highlights before the open of the U.S. stock markets on Wednesday, February 8, 2023.

Cancer & Hematology Centers of Western Michigan (CHCWM) has launched a Cancer Drug Repository (CDR) program to accept qualified unused oral cancer drug donations from individuals so they can be used for free by another Michigan resident who meets specific eligibility criteria described in state law.

Spectrum Pharmaceuticals, Inc. today announced business highlights and preliminary ROLVEDON net sales for the quarter and year ended December 31, 2022.

Biological Dynamics, a company commercializing its exosome-isolation ExoVerita™ platform, announced a collaboration with the Perlmutter Cancer Center at NYU Langone Health to validate its application for the early detection of pancreatic ductal adenocarcinoma.

Exactech, a developer and producer of innovative implants, instrumentation, and smart technologies for joint replacement surgery, announces publication of a landmark new clinical study which demonstrates the value creation associated with the rapid adoption of novel shoulder arthroplasty technologies.

Nemaura Medical, Inc. (NASDAQ: NMRD) (“Nemaura” or the “Company”) today announced the close of its previously announced registered direct offering (the “Registered Direct Offering”) with two healthcare-focused U.S. institutional investors to sell 4,796,206 shares of its common stock (the “Shares”) and warrants to purchase up to 4,796,206 Shares (the “Warrants”), in a concurrent private placement (the “Private Placement”).

Inari Medical, Inc. (NASDAQ: NARI) (“Inari”), a medical device company with a mission to treat and transform the lives of patients suffering from venous and other diseases, announced today that its management team will participate virtually at the BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference on Tuesday, February 14, 2023.

Taysha Gene Therapies, Inc. (Nasdaq: TSHA), a patient-centric, clinical -stage gene therapy company focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic rare diseases of the central nervous system (CNS), today provided an update on the TSHA-120 program in giant axonal neuropathy (GAN) and a corporate outlook for 2023.